Sorry, you need to enable JavaScript to visit this website.
Pfizer Oncology
Loading...

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Elranatamab

Geo Regions

Elranatamab

Share to an HCP

Overview + Rationale

  • B-cell maturation antigen (BCMA) is a tumor necrosis factor receptor superfamily member that is expressed predominantly on mature B cells 
  • BCMA mediates survival of antibody-secreting plasma cells after binding to its ligands BAFF (B-cell activating factor of the TNF family) and APRIL (a proliferation inducing ligand) 
  • In multiple myeloma, BCMA is widely expressed on malignant plasma cells

Mechanism of Action

Elranatamab bcmm is a bispecific B-cell maturation antigen (BCMA)-directed T-cell engaging antibody that binds BCMA on plasma cells, plasmablasts, and multiple myeloma cells and CD3 on T-cells leading to cytolysis of the BCMA-expressing cells. Elranatamab-bcmm activated T-cells caused proinflammatory cytokine release and resulted in multiple myeloma cell lysis.

Stage of Development

Elranatamab is being investigated as a single agent and in combination with other agent(s) in the following disease settings. 

small icon representing Hematologic Cancer
Relapsed/Refractory Multiple Myeloma
Phase 1B Combination

Phase 1B/2 Combination

Phase 2 Monotherapy*

Phase 3 Monotherapy

Phase 3 Monotherapy and Combination
small icon representing Hematologic Cancer
Newly Diagnosed Multiple Myeloma (Transplant Ineligible)
Phase 3 Combination
small icon representing hematologic cancer
Newly Diagnosed Multiple Myeloma (Post-Transplant Maintenance)
Phase 3 Monotherapy
small icon representing hematologic cancer
Multiple Myeloma Double–Class Exposed
Phase 3 Monotherapy and Combination
This information is current as of October 30th 2024.

*Closed to Enrollment

REFERENCES:  ELREXFIO™ (elranatamab-bccm) US Prescribing Information; Coquery CM, Erickson LD. Regulatory roles of the tumor necrosis factor receptor BCMA. Crit Rev Immunol. 2012;32:287-305. Tai YT, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/elranatamab; Anderson KC. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy. 2015;7:1187-1199; National Cancer Institute. NCI Drug Dictionary: elranatamab. Accessed May 17, 2023; Panowski et al., Mol Cancer Ther 2019;18:2008-20; ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT06215118; https://clinicaltrials.gov/study/NCT05675449; https://clinicaltrials.gov/study/NCT05090566; https://clinicaltrials.gov/study/NCT04649359; https://clinicaltrials.gov/study/NCT05020236; https://clinicaltrials.gov/study/NCT06152575; https://clinicaltrials.gov/study/NCT05317416; https://clinicaltrials.gov/study/NCT05623020.  Accessed October 21, 2024.